Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?

Roni T. Falk, Jo Ann E. Manson, Vanessa M. Barnabei, Garnet L. Anderson, Louise A. Brinton, Thomas E. Rohan, Jane A. Cauley, Chu Chen, Sally B. Coburn, Ruth M. Pfeiffer, Kerryn W. Reding, Gloria E. Sarto, Nicolas Wentzensen, Rowan T. Chlebowski, Xia Xu, Britton Trabert

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The WHI found an unexpected reduced breast cancer risk in women using CEE alone. We hypothesized CEE alone induces estrogen hydroxylation along the 2-pathway rather than the competing 16-pathway, a pattern linked to reduced postmenopausal breast cancer risk. One thousand eight hundred and sixty-four women in a WHIOS case–control study of estrogen metabolism and ovarian and endometrial cancer were studied of whom 609 were current E + P users (351 used CEE + MPA), while 272 used E alone (162 used CEE). Fifteen EM were measured, and analyses were conducted for each metabolite, hydroxylation pathway (2-, 4-, or 16-pathway) and ratios of pathway concentrations using inverse probability weighted linear regression. Compared to E + P users, all EM were higher in E alone users (significant for unconjugated estrone, total/conjugated estradiol, total/unconjugated 2-methoxyestrone, 4-methoxyestrone and unconjugated estriol). The relative concentrations of 2- and 4-pathway EM did not differ between the MHT users (2-pathway EM comprised 15% and 4-pathway EM <2% of the total), but 16-pathway EM were lower in E alone users (p = 0.036). Ratios of 2- and 4-pathway EM compared to 16-pathway EM were significantly higher in E alone compared to E + P users. Similar but not significant patterns were observed in CEE-alone and CEE + MPA users. Our data suggest that compared to E + P users, women using E alone have more extensive metabolism via the 2- vs. the competing 16-pathway. This is consistent with epidemiologic evidence of reduced postmenopausal breast cancer risk associated with this metabolic profile and may provide a clue to the breast cancer risk reduction in CEE alone users during the WHI.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Women's Health
Progestins
Observational Studies
Estrogens
Hormones
Breast Neoplasms
Hydroxylation
Estriol
Metabolome
Estrone
Risk Reduction Behavior
Endometrial Neoplasms
Ovarian Neoplasms
Estradiol
Linear Models
EM 16

Keywords

  • conjugated equine estrogens
  • conjugated equine estrogens plus medroxyprogesterone acetate
  • estrogen alone
  • estrogen metabolism
  • estrogen plus progestin
  • women's health initiative observational study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Estrogen metabolism in menopausal hormone users in the women's health initiative observational study : Does it differ between estrogen plus progestin and estrogen alone? / Falk, Roni T.; Manson, Jo Ann E.; Barnabei, Vanessa M.; Anderson, Garnet L.; Brinton, Louise A.; Rohan, Thomas E.; Cauley, Jane A.; Chen, Chu; Coburn, Sally B.; Pfeiffer, Ruth M.; Reding, Kerryn W.; Sarto, Gloria E.; Wentzensen, Nicolas; Chlebowski, Rowan T.; Xu, Xia; Trabert, Britton.

In: International Journal of Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Falk, RT, Manson, JAE, Barnabei, VM, Anderson, GL, Brinton, LA, Rohan, TE, Cauley, JA, Chen, C, Coburn, SB, Pfeiffer, RM, Reding, KW, Sarto, GE, Wentzensen, N, Chlebowski, RT, Xu, X & Trabert, B 2018, 'Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?', International Journal of Cancer. https://doi.org/10.1002/ijc.31851
Falk, Roni T. ; Manson, Jo Ann E. ; Barnabei, Vanessa M. ; Anderson, Garnet L. ; Brinton, Louise A. ; Rohan, Thomas E. ; Cauley, Jane A. ; Chen, Chu ; Coburn, Sally B. ; Pfeiffer, Ruth M. ; Reding, Kerryn W. ; Sarto, Gloria E. ; Wentzensen, Nicolas ; Chlebowski, Rowan T. ; Xu, Xia ; Trabert, Britton. / Estrogen metabolism in menopausal hormone users in the women's health initiative observational study : Does it differ between estrogen plus progestin and estrogen alone?. In: International Journal of Cancer. 2018.
@article{9bfe4f9774eb49438a3751a3fef972bd,
title = "Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?",
abstract = "The WHI found an unexpected reduced breast cancer risk in women using CEE alone. We hypothesized CEE alone induces estrogen hydroxylation along the 2-pathway rather than the competing 16-pathway, a pattern linked to reduced postmenopausal breast cancer risk. One thousand eight hundred and sixty-four women in a WHIOS case–control study of estrogen metabolism and ovarian and endometrial cancer were studied of whom 609 were current E + P users (351 used CEE + MPA), while 272 used E alone (162 used CEE). Fifteen EM were measured, and analyses were conducted for each metabolite, hydroxylation pathway (2-, 4-, or 16-pathway) and ratios of pathway concentrations using inverse probability weighted linear regression. Compared to E + P users, all EM were higher in E alone users (significant for unconjugated estrone, total/conjugated estradiol, total/unconjugated 2-methoxyestrone, 4-methoxyestrone and unconjugated estriol). The relative concentrations of 2- and 4-pathway EM did not differ between the MHT users (2-pathway EM comprised 15{\%} and 4-pathway EM <2{\%} of the total), but 16-pathway EM were lower in E alone users (p = 0.036). Ratios of 2- and 4-pathway EM compared to 16-pathway EM were significantly higher in E alone compared to E + P users. Similar but not significant patterns were observed in CEE-alone and CEE + MPA users. Our data suggest that compared to E + P users, women using E alone have more extensive metabolism via the 2- vs. the competing 16-pathway. This is consistent with epidemiologic evidence of reduced postmenopausal breast cancer risk associated with this metabolic profile and may provide a clue to the breast cancer risk reduction in CEE alone users during the WHI.",
keywords = "conjugated equine estrogens, conjugated equine estrogens plus medroxyprogesterone acetate, estrogen alone, estrogen metabolism, estrogen plus progestin, women's health initiative observational study",
author = "Falk, {Roni T.} and Manson, {Jo Ann E.} and Barnabei, {Vanessa M.} and Anderson, {Garnet L.} and Brinton, {Louise A.} and Rohan, {Thomas E.} and Cauley, {Jane A.} and Chu Chen and Coburn, {Sally B.} and Pfeiffer, {Ruth M.} and Reding, {Kerryn W.} and Sarto, {Gloria E.} and Nicolas Wentzensen and Chlebowski, {Rowan T.} and Xia Xu and Britton Trabert",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ijc.31851",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Estrogen metabolism in menopausal hormone users in the women's health initiative observational study

T2 - Does it differ between estrogen plus progestin and estrogen alone?

AU - Falk, Roni T.

AU - Manson, Jo Ann E.

AU - Barnabei, Vanessa M.

AU - Anderson, Garnet L.

AU - Brinton, Louise A.

AU - Rohan, Thomas E.

AU - Cauley, Jane A.

AU - Chen, Chu

AU - Coburn, Sally B.

AU - Pfeiffer, Ruth M.

AU - Reding, Kerryn W.

AU - Sarto, Gloria E.

AU - Wentzensen, Nicolas

AU - Chlebowski, Rowan T.

AU - Xu, Xia

AU - Trabert, Britton

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The WHI found an unexpected reduced breast cancer risk in women using CEE alone. We hypothesized CEE alone induces estrogen hydroxylation along the 2-pathway rather than the competing 16-pathway, a pattern linked to reduced postmenopausal breast cancer risk. One thousand eight hundred and sixty-four women in a WHIOS case–control study of estrogen metabolism and ovarian and endometrial cancer were studied of whom 609 were current E + P users (351 used CEE + MPA), while 272 used E alone (162 used CEE). Fifteen EM were measured, and analyses were conducted for each metabolite, hydroxylation pathway (2-, 4-, or 16-pathway) and ratios of pathway concentrations using inverse probability weighted linear regression. Compared to E + P users, all EM were higher in E alone users (significant for unconjugated estrone, total/conjugated estradiol, total/unconjugated 2-methoxyestrone, 4-methoxyestrone and unconjugated estriol). The relative concentrations of 2- and 4-pathway EM did not differ between the MHT users (2-pathway EM comprised 15% and 4-pathway EM <2% of the total), but 16-pathway EM were lower in E alone users (p = 0.036). Ratios of 2- and 4-pathway EM compared to 16-pathway EM were significantly higher in E alone compared to E + P users. Similar but not significant patterns were observed in CEE-alone and CEE + MPA users. Our data suggest that compared to E + P users, women using E alone have more extensive metabolism via the 2- vs. the competing 16-pathway. This is consistent with epidemiologic evidence of reduced postmenopausal breast cancer risk associated with this metabolic profile and may provide a clue to the breast cancer risk reduction in CEE alone users during the WHI.

AB - The WHI found an unexpected reduced breast cancer risk in women using CEE alone. We hypothesized CEE alone induces estrogen hydroxylation along the 2-pathway rather than the competing 16-pathway, a pattern linked to reduced postmenopausal breast cancer risk. One thousand eight hundred and sixty-four women in a WHIOS case–control study of estrogen metabolism and ovarian and endometrial cancer were studied of whom 609 were current E + P users (351 used CEE + MPA), while 272 used E alone (162 used CEE). Fifteen EM were measured, and analyses were conducted for each metabolite, hydroxylation pathway (2-, 4-, or 16-pathway) and ratios of pathway concentrations using inverse probability weighted linear regression. Compared to E + P users, all EM were higher in E alone users (significant for unconjugated estrone, total/conjugated estradiol, total/unconjugated 2-methoxyestrone, 4-methoxyestrone and unconjugated estriol). The relative concentrations of 2- and 4-pathway EM did not differ between the MHT users (2-pathway EM comprised 15% and 4-pathway EM <2% of the total), but 16-pathway EM were lower in E alone users (p = 0.036). Ratios of 2- and 4-pathway EM compared to 16-pathway EM were significantly higher in E alone compared to E + P users. Similar but not significant patterns were observed in CEE-alone and CEE + MPA users. Our data suggest that compared to E + P users, women using E alone have more extensive metabolism via the 2- vs. the competing 16-pathway. This is consistent with epidemiologic evidence of reduced postmenopausal breast cancer risk associated with this metabolic profile and may provide a clue to the breast cancer risk reduction in CEE alone users during the WHI.

KW - conjugated equine estrogens

KW - conjugated equine estrogens plus medroxyprogesterone acetate

KW - estrogen alone

KW - estrogen metabolism

KW - estrogen plus progestin

KW - women's health initiative observational study

UR - http://www.scopus.com/inward/record.url?scp=85056117414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056117414&partnerID=8YFLogxK

U2 - 10.1002/ijc.31851

DO - 10.1002/ijc.31851

M3 - Article

C2 - 30183089

AN - SCOPUS:85056117414

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -